Performance of Surveillance Case Definitions in Detecting Respiratory Syncytial Virus Infection Among Young Children Hospitalized With Severe Respiratory Illness-South Africa, 2009-2014.


Journal

Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049

Informations de publication

Date de publication:
25 Sep 2019
Historique:
received: 14 12 2017
accepted: 05 06 2018
pubmed: 23 6 2018
medline: 3 3 2020
entrez: 23 6 2018
Statut: ppublish

Résumé

Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection (ALRTI) in young children, but data on surveillance case definition performance in estimating burdens have been limited. We enrolled children aged <5 years hospitalized for ALRTI (or neonatal sepsis in young infants) through active prospective surveillance at 5 sentinel hospitals in South Africa and collected nasopharyngeal aspirates from them for RSV molecular diagnostic testing between 2009 and 2014. Clinical data were used to characterize RSV disease and retrospectively evaluate the performance of respiratory illness case definitions (including the World Health Organization definition for severe acute respiratory infection [SARI]) in identifying hospitalized children with laboratory-confirmed RSV according to age group (<3, 3-5, 6-11, 12-23, and 24-59 months). Of 9969 hospitalized children, 2723 (27%) tested positive for RSV. Signs and symptoms in RSV-positive children varied according to age; fever was less likely to occur in children aged <3 months (57%; odds ratio [OR], 0.8 [95% CI, 0.7-0.9]) but more likely in those aged ≥12 months (82%; OR, 1.7-1.9) than RSV-negative children. The sensitivity (range, 55%-81%) and specificity (range, 27%-54%) of the SARI case definition to identify hospitalized RSV-positive children varied according to age; the lowest sensitivity was for infants aged <6 months. Using SARI as the case definition would have missed 36% of RSV-positive children aged <5 years and 49% of those aged <3 months; removing the fever requirement from the definition recovered most missed cases. Including fever in the SARI case definition lowers the sensitivity for RSV case detection among young children hospitalized with an ALRTI and likely underestimates its burden.

Sections du résumé

BACKGROUND BACKGROUND
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infection (ALRTI) in young children, but data on surveillance case definition performance in estimating burdens have been limited.
METHODS METHODS
We enrolled children aged <5 years hospitalized for ALRTI (or neonatal sepsis in young infants) through active prospective surveillance at 5 sentinel hospitals in South Africa and collected nasopharyngeal aspirates from them for RSV molecular diagnostic testing between 2009 and 2014. Clinical data were used to characterize RSV disease and retrospectively evaluate the performance of respiratory illness case definitions (including the World Health Organization definition for severe acute respiratory infection [SARI]) in identifying hospitalized children with laboratory-confirmed RSV according to age group (<3, 3-5, 6-11, 12-23, and 24-59 months).
RESULTS RESULTS
Of 9969 hospitalized children, 2723 (27%) tested positive for RSV. Signs and symptoms in RSV-positive children varied according to age; fever was less likely to occur in children aged <3 months (57%; odds ratio [OR], 0.8 [95% CI, 0.7-0.9]) but more likely in those aged ≥12 months (82%; OR, 1.7-1.9) than RSV-negative children. The sensitivity (range, 55%-81%) and specificity (range, 27%-54%) of the SARI case definition to identify hospitalized RSV-positive children varied according to age; the lowest sensitivity was for infants aged <6 months. Using SARI as the case definition would have missed 36% of RSV-positive children aged <5 years and 49% of those aged <3 months; removing the fever requirement from the definition recovered most missed cases.
CONCLUSION CONCLUSIONS
Including fever in the SARI case definition lowers the sensitivity for RSV case detection among young children hospitalized with an ALRTI and likely underestimates its burden.

Identifiants

pubmed: 29931284
pii: 5042080
doi: 10.1093/jpids/piy055
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

325-333

Subventions

Organisme : NCIRD CDC HHS
ID : U01 IP001048
Pays : United States

Informations de copyright

Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society 2018.

Auteurs

Brian Rha (B)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia.

Rebecca M Dahl (RM)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia.
Maximus Federal, Atlanta, Georgia.

Jocelyn Moyes (J)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.
School of Public Health, Faculty of Health Sciences, Johannesburg, South Africa.

Alison M Binder (AM)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia.
Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee.

Stefano Tempia (S)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.

Sibongile Walaza (S)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.
School of Public Health, Faculty of Health Sciences, Johannesburg, South Africa.

Daoling Bi (D)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia.

Michelle J Groome (MJ)

Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, Johannesburg, South Africa.
Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Johannesburg, South Africa.

Ebrahim Variava (E)

Department of Medicine, Faculty of Health Sciences, Johannesburg, South Africa.
Perinatal HIV Research Unit (PHRU), SAMRC Soweto Matlosana Collaborative Centre for HIV/AIDS and TB, Johannesburg, South Africa.
Department of Medicine, Klerksdorp Tshepong Hospital, South Africa.

Fathima Naby (F)

Department of Paediatrics, Pietermaritzburg Metropolitan Hospitals, University of KwaZulu-Natal, South Africa.

Kathleen Kahn (K)

MRC/Wits Rural Public Health and Health Transitions Research Unit (Agincourt), School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
Centre for Global Health Research, Umeå University, Sweden.
INDEPTH Network, Accra, Ghana.

Florette Treurnicht (F)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.

Adam L Cohen (AL)

Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.
Department of Immunizations, Vaccines, and Biologicals, World Health Organization, Geneva, Switzerland.

Susan I Gerber (SI)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Atlanta, Georgia.

Shabir A Madhi (SA)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.
Medical Research Council, Respiratory and Meningeal Pathogens Research Unit, Faculty of Health Sciences, Johannesburg, South Africa.
Department of Science and Technology/National Research Foundation: Vaccine Preventable Diseases, Johannesburg, South Africa.

Cheryl Cohen (C)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases, Johannesburg, South Africa.
School of Public Health, Faculty of Health Sciences, Johannesburg, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH